Want to see TSE:EPIC full AI Analyst Report?
Top Page
1CM Inc
(EPIC)
Select Model
Select Model
Rating:63Neutral
Price Target:
C$0.41
▲(10.81% Upside)
Action:Reiterated
Date:08/29/26
The score is driven mainly by improving financial performance (rapid revenue growth, a profitability turnaround, and low balance-sheet leverage), tempered by meaningful risks around earnings quality (very thin gross margin) and weak cash conversion (negative free cash flow). Technically the trend is strong, but extremely overbought signals reduce the near-term technical score. Valuation is supportive due to a low P/E, though dividend support is not available.
Positive Factors
Rapid Revenue Growth
Revenue scaling of approximately 54% demonstrates strong recent top-line momentum and expanding business activity. If sustained, this growth can improve operating leverage, support reinvestment, and strengthen the company’s ability to build a more durable earnings base over the next several quarters.
Negative Factors
Extremely Thin Gross Margin
A gross margin near 1% leaves very little room to absorb cost increases, pricing pressure, or changes in product mix. The decline from roughly 9% also raises concern about earnings durability, since modest operational setbacks could materially reduce or eliminate reported profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid Revenue Growth
Revenue scaling of approximately 54% demonstrates strong recent top-line momentum and expanding business activity. If sustained, this growth can improve operating leverage, support reinvestment, and strengthen the company’s ability to build a more durable earnings base over the next several quarters.
Read all positive factors
1CM Inc (EPIC) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$45.33M
Dividend YieldN/A
Average Volume (3M)8.31K
Price to Earnings (P/E)9.6
Beta (1Y)1.01
Revenue Growth7.36%
EPS Growth172.97%
CountryCA
Employees11
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.04
Shares Outstanding117,736,940
10 Day Avg. Volume16,191
30 Day Avg. Volume8,313
Financial Highlights & Ratios
PEG Ratio-2.71
Price to Book (P/B)0.96
Price to Sales (P/S)0.38
P/FCF Ratio11.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
1CM Inc Business Overview & Revenue Model
Company Description
1CM Inc. functions as a diverse enterprise within the cannabis industry. The company's primary focus is on utilizing technology to cater to individual consumers, with the objective of making cannabis markets more accessible and inclusive. Previous...
How the Company Makes Money
Publicly available, company-specific detail on 1CM Inc.’s current revenue model and major revenue streams is not available with sufficient specificity to describe factually without speculation; therefore null....
1CM Inc Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
78
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Nov 2025 | Nov 2024 | Aug 2023 | Nov 2022 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 75.45M | 73.37M | 57.22M | 35.34M | 842.49K | 341.81K |
| Gross Profit | 875.02K | 6.65M | 11.18M | 7.61M | -428.00K | -148.00K |
| EBITDA | 2.92M | 2.88M | 2.86M | 1.31M | -3.36M | -3.57M |
| Net Income | 4.75M | 484.85K | 615.91K | -914.00K | -4.73M | -4.56M |
Balance Sheet | ||||||
| Total Assets | 44.31M | 43.52M | 39.87M | 34.02M | 28.23M | 9.32M |
| Cash, Cash Equivalents and Short-Term Investments | 9.61M | 6.15M | 4.97M | 3.08M | 2.24M | 162.46K |
| Total Debt | 1.54M | 3.42M | 7.85M | 6.39M | 11.13M | 12.26M |
| Total Liabilities | 10.29M | 14.65M | 12.14M | 9.42M | 12.85M | 13.78M |
| Stockholders Equity | 34.02M | 28.87M | 27.73M | 24.60M | 15.38M | -3.85M |
Cash Flow | ||||||
| Free Cash Flow | -169.59K | 2.51M | 762.99K | -4.37M | -2.75M | -2.01M |
| Operating Cash Flow | 329.50K | 2.71M | 2.47M | -1.75M | -2.53M | -1.99M |
| Investing Cash Flow | 3.67M | -627.84K | -1.71M | 1.33M | 1.75M | -150.80K |
| Financing Cash Flow | -2.98M | -1.57M | 1.13M | 1.26M | 2.85M | 2.30M |
1CM Inc Technical Analysis
Positive
0.37
Price Trends
0.18
Positive
0.17
Positive
0.18
Positive
Market Momentum
0.07
Negative
66.34
Neutral
49.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EPIC, the sentiment is Positive. The current price of 0.37 is above the 20-day moving average (MA) of 0.28, above the 50-day MA of 0.18, and above the 200-day MA of 0.18, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 66.34 is Neutral, neither overbought nor oversold. The STOCH value of 49.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:EPIC.
1CM Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | C$45.33M | 9.55 | 15.10% | ― | 7.36% | 172.97% | |
55 Neutral | C$32.44M | -19.51 | -4.00% | ― | 16.66% | -1007.41% | |
53 Neutral | C$32.04M | -6.47 | -13.79% | ― | -6.74% | 43.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | C$17.47M | -4.01 | -108.44% | ― | -0.23% | -142.54% | |
41 Neutral | C$11.21M | -3.21 | 28.59% | ― | 0.90% | 57.73% | |
41 Neutral | C$10.66M | -3.62 | -35.33% | ― | -1.41% | -78.91% |
* Healthcare Sector Average
TSE:EPIC
1CM Inc
0.39
>-0.01
-1.28%
TSE:LABS
MediPharm Labs
0.08
<0.01
7.14%
TSE:PCLO
PharmaCielo
0.06
0.02
33.33%
TSE:ROMJ
Rubicon Organics
0.48
-0.09
-15.79%
TSE:AVCN
Avicanna
0.13
-0.14
-51.85%
TSE:GWAY
Greenway Greenhouse Cannabis Corp.
0.08
-0.13
-61.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.